Health

FDA Approves Nereus (tradipitant) for the Prevention of Motion Sickness

DailyTrendDailyTrend
Jan 4, 2026 - 03:00
 0  1
WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Nereus (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Electronic Homecare Bed Correction: Medline Updates Use Instructions for Homecare Beds

Electronic Homecare Bed Correction: Medline Updates Use...

DailyTrend Feb 17, 2026  0  1

Glucose Monitor Sensor Recall: Abbott Diabetes Care Removes Certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors

Glucose Monitor Sensor Recall: Abbott Diabetes Care Rem...

DailyTrend Feb 12, 2026  0  0

Emergency Response Safety Kit Recall: Airlife Removes Certain Broselow Pediatric Emergency Rainbow Tapes and Broselow ALS Organizers

Emergency Response Safety Kit Recall: Airlife Removes C...

DailyTrend Feb 12, 2026  0  0

New Method Can Find Hidden Eggs to Aid in Fertility Treatment

New Method Can Find Hidden Eggs to Aid in Fertility Tre...

DailyTrend Feb 12, 2026  0  0

Senate Questions Health Care Firm for Profiting Off Program Meant for Poor

Senate Questions Health Care Firm for Profiting Off Pro...

DailyTrend Feb 12, 2026  0  1

FDA Approves Yuvezzi (carbachol and brimonidine tartrat...

DailyTrend Jan 30, 2026  0  1